Chinese licorice: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only) |
m Move references inside PlantMedTemplate call (fix phantom leading paragraphs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
| image = | | image = | ||
| intro = Chinese licorice (''Glycyrrhiza uralensis'' Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species ''G. glabra'' (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at [[Western licorice]]. Both species are routinely substituted in commerce without pharmacopoeia distinction. | | intro = Chinese licorice (''Glycyrrhiza uralensis'' Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species ''G. glabra'' (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at [[Western licorice]]. Both species are routinely substituted in commerce without pharmacopoeia distinction. | ||
| taxonomy = ''Glycyrrhiza uralensis'' Fisch. ex DC. belongs to tribe Galegeae, family Fabaceae, one of approximately thirty species in the genus ''Glycyrrhiza''. The genus name derives from the Greek glykys (sweet) and rhiza (root), reflecting the intensely sweet taproot shared across the genus. ''G. uralensis'' is distinguished from ''G. glabra'' (European licorice) by glandular-hairy stems and seed pods, a more compact and shorter flower raceme, and a tendency to form dense rhizome mats in the steppe and semi-arid grasslands it inhabits; these morphological distinctions are unreliable in dried commercial root stock, and commercial substitution of the two species is routine and pharmacopoeially sanctioned under most major pharmacopoeias. ''G. inflata'' (Xinjiang licorice) is a third commercially significant species, particularly sourced in Central Asian markets. | | taxonomy = ''Glycyrrhiza uralensis'' Fisch. ex DC. belongs to tribe Galegeae, family Fabaceae, one of approximately thirty species in the genus ''Glycyrrhiza''. The genus name derives from the Greek glykys (sweet) and rhiza (root), reflecting the intensely sweet taproot shared across the genus. ''G. uralensis'' is distinguished from ''G. glabra'' (European licorice) by glandular-hairy stems and seed pods, a more compact and shorter flower raceme, and a tendency to form dense rhizome mats in the steppe and semi-arid grasslands it inhabits; these morphological distinctions are unreliable in dried commercial root stock, and commercial substitution of the two species is routine and pharmacopoeially sanctioned under most major pharmacopoeias. ''G. inflata'' (Xinjiang licorice) is a third commercially significant species, particularly sourced in Central Asian markets. | ||
The medicinal parts are the root and rhizome, harvested from plants four years or older; roots from younger plants have lower glycyrrhizin content and are considered suboptimal quality. In TCM practice the dried root is processed in two clinically distinct forms: sheng gan cao (生甘草, raw or unprocessed dried root), used for fire-toxicity conditions and as the universal harmonizing constituent; and zhi gan cao (炙甘草, honey-fried root), prepared by combining sliced dry root with liquid honey (typically 25 g honey per 100 g dry root) and stir-frying over gentle heat until the honey is fully absorbed and the surface is fragrant and golden-brown. TCM processing theory holds that honey-frying shifts the root's properties from the neutral-cooling of the raw form toward a warmer, more tonifying quality particularly suited to heart-calming and spleen-tonifying indications. | The medicinal parts are the root and rhizome, harvested from plants four years or older; roots from younger plants have lower glycyrrhizin content and are considered suboptimal quality. In TCM practice the dried root is processed in two clinically distinct forms: sheng gan cao (生甘草, raw or unprocessed dried root), used for fire-toxicity conditions and as the universal harmonizing constituent; and zhi gan cao (炙甘草, honey-fried root), prepared by combining sliced dry root with liquid honey (typically 25 g honey per 100 g dry root) and stir-frying over gentle heat until the honey is fully absorbed and the surface is fragrant and golden-brown. TCM processing theory holds that honey-frying shifts the root's properties from the neutral-cooling of the raw form toward a warmer, more tonifying quality particularly suited to heart-calming and spleen-tonifying indications. | ||
| traditional_uses = '''Chinese medicine (primary centroid)''' | | traditional_uses = '''Chinese medicine (primary centroid)''' | ||
| Line 33: | Line 31: | ||
''G. uralensis'' has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in ''G. glabra'', the Mediterranean species. ''G. uralensis'' enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at [[Western licorice]]. | ''G. uralensis'' has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in ''G. glabra'', the Mediterranean species. ''G. uralensis'' enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at [[Western licorice]]. | ||
| preparations = Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction. | | preparations = Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction. | ||
| Line 43: | Line 40: | ||
Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from ''G. glabra'' material; ''G. uralensis''-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at [[Western licorice]]. | Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from ''G. glabra'' material; ''G. uralensis''-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at [[Western licorice]]. | ||
| pharmacology = '''Principal active constituents''' | | pharmacology = '''Principal active constituents''' | ||
| Line 53: | Line 49: | ||
Glycyrrhetic acid (enoxolone): the free aglycone of glycyrrhizin; the basis of the pharmaceutical derivative carbenoxolone, the synthetic peptic ulcer compound developed in Europe in the 1960s to 1970s, documented at [[Western licorice]]. | Glycyrrhetic acid (enoxolone): the free aglycone of glycyrrhizin; the basis of the pharmaceutical derivative carbenoxolone, the synthetic peptic ulcer compound developed in Europe in the 1960s to 1970s, documented at [[Western licorice]]. | ||
| indications = '''TCM indications (primary)''' | | indications = '''TCM indications (primary)''' | ||
| Line 71: | Line 66: | ||
Western clinical research on licorice does not systematically distinguish ''G. uralensis'' from ''G. glabra''; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at [[Western licorice]]. | Western clinical research on licorice does not systematically distinguish ''G. uralensis'' from ''G. glabra''; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at [[Western licorice]]. | ||
| dosing = TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.<ref name="bensky2004"/> | | dosing = TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.<ref name="bensky2004"/> | ||
| Line 77: | Line 71: | ||
Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both ''G. uralensis'' and ''G. glabra''. | Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both ''G. uralensis'' and ''G. glabra''. | ||
| pharmacokinetics = Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility. | | pharmacokinetics = Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility. | ||
| Line 83: | Line 76: | ||
The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at [[Western licorice]]. | The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at [[Western licorice]]. | ||
| interactions = The interaction profile of ''G. uralensis'' is identical to that of ''G. glabra''; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at [[Western licorice]]; the following is a clinical summary. | | interactions = The interaction profile of ''G. uralensis'' is identical to that of ''G. glabra''; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at [[Western licorice]]; the following is a clinical summary. | ||
| Line 97: | Line 89: | ||
DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions. | DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions. | ||
| interactionsummary = Antihypertensives (antagonism of blood pressure control), potassium-depleting agents including loop and thiazide diuretics and corticosteroids (additive hypokalemia), cardiac glycosides including digoxin (hypokalemia-mediated toxicity potentiation), exogenous corticosteroids (amplification of mineralocorticoid effects). Full DDI discussion at [[Western licorice]]. DGL preparations avoid these interactions. | | interactionsummary = Antihypertensives (antagonism of blood pressure control), potassium-depleting agents including loop and thiazide diuretics and corticosteroids (additive hypokalemia), cardiac glycosides including digoxin (hypokalemia-mediated toxicity potentiation), exogenous corticosteroids (amplification of mineralocorticoid effects). Full DDI discussion at [[Western licorice]]. DGL preparations avoid these interactions. | ||
| safety = The pseudohyperaldosteronism safety profile of ''G. uralensis'' is identical to that of ''G. glabra'': the same 18-beta-glycyrrhetinic-acid-mediated 11-beta-HSD2 inhibition, the same dose-dependent sodium retention, potassium depletion, hypertension, and edema, and the same case-report and regulatory literature. The full mechanism, dose-response, Walker 1994, van Uum 2005, and EU SCF 2003 guidance are documented at [[Western licorice]]. The 100 mg/day glycyrrhizin chronic-use limit applies to whole-licorice preparations of either species. | | safety = The pseudohyperaldosteronism safety profile of ''G. uralensis'' is identical to that of ''G. glabra'': the same 18-beta-glycyrrhetinic-acid-mediated 11-beta-HSD2 inhibition, the same dose-dependent sodium retention, potassium depletion, hypertension, and edema, and the same case-report and regulatory literature. The full mechanism, dose-response, Walker 1994, van Uum 2005, and EU SCF 2003 guidance are documented at [[Western licorice]]. The 100 mg/day glycyrrhizin chronic-use limit applies to whole-licorice preparations of either species. | ||
| Line 107: | Line 97: | ||
Contraindications: hypertension, hypokalemia, cardiac arrhythmia, hepatic cirrhosis, renal insufficiency, concurrent use of potassium-depleting agents or cardiac glycosides, and pregnancy at high doses. | Contraindications: hypertension, hypokalemia, cardiac arrhythmia, hepatic cirrhosis, renal insufficiency, concurrent use of potassium-depleting agents or cardiac glycosides, and pregnancy at high doses. | ||
| monitoring = Whole-licorice use (any form of ''G. uralensis'' root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops. | | monitoring = Whole-licorice use (any form of ''G. uralensis'' root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops. | ||
| Line 113: | Line 102: | ||
DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed. | DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed. | ||
| counseling = The pseudohyperaldosteronism risk that applies to Western licorice (''G. glabra'') applies equally to Chinese licorice (''G. uralensis'') and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information. | | counseling = The pseudohyperaldosteronism risk that applies to Western licorice (''G. glabra'') applies equally to Chinese licorice (''G. uralensis'') and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information. | ||
| Line 123: | Line 111: | ||
The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation. | The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation. | ||
| history = Gan cao's written history in Chinese medicine extends to the earliest stratum of the Chinese herbal record. The Shennong Ben Cao Jing (first to second century CE) placed it among the 120 upper herbs, the highest-quality classification available in the text's tripartite system, signaling that its safety and tonic utility were already well established by the Han dynasty period (206 BCE to 220 CE) when the text was compiled.{{citation needed}}<!-- Same candidate as traditional_uses above: Yang SZ 1998 Blue Poppy Press translation. --> | | history = Gan cao's written history in Chinese medicine extends to the earliest stratum of the Chinese herbal record. The Shennong Ben Cao Jing (first to second century CE) placed it among the 120 upper herbs, the highest-quality classification available in the text's tripartite system, signaling that its safety and tonic utility were already well established by the Han dynasty period (206 BCE to 220 CE) when the text was compiled.{{citation needed}}<!-- Same candidate as traditional_uses above: Yang SZ 1998 Blue Poppy Press translation. --> | ||
| Line 133: | Line 120: | ||
Contemporary ''G. uralensis'' populations are subject to conservation pressure from commercial wild harvesting in Inner Mongolia, Gansu, and Xinjiang; overharvesting has substantially reduced wild stands over the past several decades, driving the industry toward cultivated supply. ''Glycyrrhiza'' species are subject to trade-monitoring frameworks requiring country-of-origin export documentation to verify sustainable sourcing.{{citation needed}}<!-- Candidate: CITES (Convention on International Trade in Endangered Species) species database at cites.org; check current Appendix listing and any annotation for ''Glycyrrhiza'' spp. Also: Zhao ZL et al, Journal of Ethnopharmacology 2015 or similar, on ''Glycyrrhiza uralensis'' wild resource decline in China. Topic: CITES listing status (if any) for ''Glycyrrhiza'' species; conservation status of wild ''G. uralensis'' in Inner Mongolia and Xinjiang. Verify at publish before confirming the CITES Appendix claim specifically. --> ''G. uralensis'' is listed in the Pharmacopoeia of the People's Republic of China as an official medicinal herb under the monograph Gan Cao (甘草), and the pharmacopoeia specification includes a minimum glycyrrhizin content standard as a quality criterion, shaping commercial cultivation toward higher-yielding varieties.<ref name="chinpharmacopoeia2020"/> | Contemporary ''G. uralensis'' populations are subject to conservation pressure from commercial wild harvesting in Inner Mongolia, Gansu, and Xinjiang; overharvesting has substantially reduced wild stands over the past several decades, driving the industry toward cultivated supply. ''Glycyrrhiza'' species are subject to trade-monitoring frameworks requiring country-of-origin export documentation to verify sustainable sourcing.{{citation needed}}<!-- Candidate: CITES (Convention on International Trade in Endangered Species) species database at cites.org; check current Appendix listing and any annotation for ''Glycyrrhiza'' spp. Also: Zhao ZL et al, Journal of Ethnopharmacology 2015 or similar, on ''Glycyrrhiza uralensis'' wild resource decline in China. Topic: CITES listing status (if any) for ''Glycyrrhiza'' species; conservation status of wild ''G. uralensis'' in Inner Mongolia and Xinjiang. Verify at publish before confirming the CITES Appendix claim specifically. --> ''G. uralensis'' is listed in the Pharmacopoeia of the People's Republic of China as an official medicinal herb under the monograph Gan Cao (甘草), and the pharmacopoeia specification includes a minimum glycyrrhizin content standard as a quality criterion, shaping commercial cultivation toward higher-yielding varieties.<ref name="chinpharmacopoeia2020"/> | ||
| effects = | | effects = | ||
| traditional_geography = | | traditional_geography = | ||
| anecdotes = | | anecdotes = | ||
| references = <references/> | |||
}} | }} | ||
[[Category:Plants]] | [[Category:Plants]] | ||
Latest revision as of 20:59, 26 May 2026
| Summary | |
|---|---|
| Binomial | Glycyrrhiza uralensis |
| Family | Fabaceae |
| Native range | Northern China, Mongolia, Siberia, and Central Asia; wild stands in Xinjiang, Gansu, Inner Mongolia, and Manchuria; commercial supply largely from cultivated stands in northern and northwestern China. |
| Pharmacy | |
| Pharmacology | |
Chinese licorice (Glycyrrhiza uralensis Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species G. glabra (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at Western licorice. Both species are routinely substituted in commerce without pharmacopoeia distinction.
History and traditional use
Chinese medicine (primary centroid)
The earliest written record of gan cao is in the Shennong Ben Cao Jing (神农本草经, Divine Farmer's Classic of Materia Medica), the foundational Chinese pharmacopoeia compiled approximately between the first and second centuries of the common era.[citation needed] The Shennong Ben Cao Jing categorized all 365 medicinal substances into three tiers: 120 upper herbs (上品, shàng pǐn), considered tonic and safe for prolonged use; 120 middle herbs, with specific therapeutic actions and moderate safety considerations; and 125 lower herbs, potent or toxic and reserved for acute conditions. Gan cao was classified as an upper herb, the most favorable designation in the text, a judgment that prefigured its two-thousand-year career as the universal harmonizing tonic base of Chinese formula construction.
The feature of gan cao that defines its clinical identity, and that has no close analog in Western pharmacological thinking, is its role as the harmonizer of formulas (调和诸药, tiáo hé zhū yào). Bensky, Clavey, and Stoger document gan cao's presence in approximately sixty percent of all classical Chinese herbal formulae,[1] a frequency no other single herb approaches, reflecting a function performed at the formula level rather than the organ-system level. Bensky identifies three distinct harmonizing roles that collectively account for this ubiquity.[1] First, gan cao moderates the toxicity and harshness of potent formula ingredients: where aconite (fu zi, a potent yang-warming root with a narrow therapeutic window), coptis (huang lian, intensely bitter and cold), or other drastic herbs appear, gan cao is the standard buffer, softening action and preventing the formula from overshooting its therapeutic purpose. Second, it harmonizes herbs of divergent thermal properties, flavors, and organ tropisms, preventing the "qi conflict" that TCM theory associates with unmediated confrontations between cold and hot, or ascending and descending, formula components. Third, it protects the stomach and spleen from the irritating effects of harsh ingredients, supporting patient tolerability through extended decoction courses. So thoroughgoing was this mediating function in the view of later TCM physicians that gan cao acquired the court honorific 国老 (guó lǎo, "Elder Statesman" or "Grand Councillor of the Nation"), comparing the herb's role in a formula to that of a senior official who mediates among warring ministers, integrates competing interests, and supports the sovereign's governing intention without seeking prominence for its own office.[1]
Zhang Zhongjing compiled the Shang Han Lun (伤寒论, Treatise on Cold Damage Disorders) approximately 210 CE; together with its companion the Jin Gui Yao Lue (金匮要略, Essential Prescriptions of the Golden Cabinet), it codified the classical formula architecture that remains foundational in contemporary TCM practice.[citation needed] Gan cao appears in a large proportion of the Shang Han Lun's one hundred and thirteen prescriptions. Four formulae from this text are of particular clinical significance and continue in active contemporary use:
Gan Cao Tang (甘草汤, Licorice Decoction) is the simplest formula: sheng gan cao as the sole herb, at full therapeutic dose, for sore throat and fire-toxicity patterns of the throat. It exemplifies gan cao in its direct anti-toxicity function rather than in the harmonizing role.[1]
Zhi Gan Cao Tang (炙甘草汤, Honey-Fried Licorice Decoction), also known as Fumai Tang (复脉汤, Restore the Pulse Decoction), is a nine-ingredient formula combining honey-fried licorice as the principal herb with Rehmannia glutinosa (di huang), Ophiopogon japonicus (mai men dong), Colla Corii Asini (e jiao, donkey-hide gelatin), Cannabis sativa seed (huo ma ren), dried ginger (gan jiang), cinnamon twig (gui zhi; the same herb as Cassia cinnamon in TCM usage), jujube (da zao), and sake. It is prescribed specifically for heart palpitations (心悸, xīn jì) and irregularly or regularly irregular pulse arising from deficiency of heart yin and heart yang.[citation needed] Zhi Gan Cao Tang is the most specific TCM cardiac-rhythm prescription in the Shang Han Lun and remains a subject of contemporary pharmacological and small-scale clinical research.
Shao Yao Gan Cao Tang (芍药甘草汤, Peony and Licorice Decoction) pairs white peony root (bai shao, Paeonia lactiflora) with honey-fried gan cao in a two-herb formula prescribed for muscular spasm and cramping, particularly abdominal spasm and lower-limb cramps. The combination has attracted modern pharmacognosy investigation: paeoniflorin, the principal active glycoside of white peony, and glycyrrhizin appear to produce antispasmodic effects in animal models that exceed either constituent alone, with paeoniflorin and glycyrrhetinic acid proposed as synergistic components acting through distinct but complementary antispasmodic pathways.[citation needed]
Si Jun Zi Tang (四君子汤, Four Gentlemen Decoction) combines ginseng (ren shen, Panax ginseng), white atractylodes (bai zhu, Atractylodes macrocephala), poria (fu ling, Wolfiporia cocos), and honey-fried licorice. It is the foundational spleen-qi tonic of TCM, the structural core from which a large family of derivative tonifying and digestive-support formulae is built, including Liu Jun Zi Tang (Six Gentlemen), Xiang Sha Liu Jun Zi Tang, and numerous others.[citation needed] Gan cao's role in Si Jun Zi Tang is primarily harmonizing and stomach-protective rather than directly tonifying; the principal tonifying agents are ginseng and white atractylodes, with gan cao integrating their divergent properties and protecting the stomach from the full impact of concentrated qi-supplementing herbs.
Li Shizhen's Ben Cao Gang Mu (本草纲目, Compendium of Materia Medica), completed in 1578 and published in 1596, gave gan cao its most comprehensive classical Chinese treatment, cataloguing morphological varieties, regional origins, harvesting protocols, processing methods (with particular attention to the honey-frying distinction), flavors, thermal properties, organ tropisms, formulaic combinations, and the guó lǎo honorific as a tradition tracing to the Han dynasty.[citation needed] Li Shizhen's synthesis made the Ben Cao Gang Mu the de facto reference standard for East Asian herbal medicine from the Ming dynasty onward.
Western herbal and Ayurvedic use (brief)
G. uralensis has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in G. glabra, the Mediterranean species. G. uralensis enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at Western licorice.
Preparations
Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction.
Zhi gan cao (炙甘草, honey-fried root): root stir-fried with liquid honey until fragrant and golden-brown; TCM processing theory holds that honey-frying intensifies tonifying and warmth-generating properties while moderating bitterness and astringency. Specified for spleen-qi tonification, heart palpitations (particularly in the Zhi Gan Cao Tang formula), and all indications where a warming-tonifying rather than cooling-clearing action is required.
Standardized root extract: concentrated extract standardized to 18 to 25 percent glycyrrhizin content, available as solid extract or liquid concentrate; both G. uralensis and G. glabra are sourced commercially for standardized extracts, frequently without species designation on product labels.
TCM granule extract: spray-dried or freeze-dried root extract in granule form for contemporary TCM granule-prescription practice, allowing formula assembly without traditional decoction; commercially available as sheng gan cao or zhi gan cao granules.
Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from G. glabra material; G. uralensis-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at Western licorice.
Pharmacokinetics
Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility.
18-Beta-glycyrrhetinic acid: half-life approximately 7 to 8 hours; primarily hepatic metabolism; biliary excretion with enterohepatic recirculation reported, potentially prolonging effective exposure with repeated daily dosing.
The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at Western licorice.
Experience
Log in to add your own experience.
Problems
TCM indications (primary)
Spleen qi deficiency: fatigue, diminished appetite, loose stools, and lassitude; honey-fried gan cao as a constituent of tonifying formulae, principally Si Jun Zi Tang and its extensive derivative family; the most frequently invoked TCM indication in formula construction.[1]
Heart palpitations and irregularly irregular pulse from deficiency of heart yin and heart yang: the specific indication of the Zhi Gan Cao Tang formula; among the more physiologically specific classical TCM cardiac-rhythm indications and a subject of contemporary pharmacological and small-scale clinical investigation, including case reports of formula modifications for both bradyarrhythmia and tachyarrhythmia.[1][2]
Lung dryness and cough: raw gan cao in wind-heat or lung-dryness patterns; gan cao moistens the lung channel and moderates the drying effect of other herbs in respiratory formulae.[1]
Fire toxicity: carbuncles, boils, and sore throat with heat characteristics; raw gan cao as Gan Cao Tang alone or combined with other heat-clearing herbs; one of the direct therapeutic indications in which gan cao functions as the principal herb rather than as a harmonizer.[1]
Lower-limb and abdominal muscular spasm: Shao Yao Gan Cao Tang (white peony and honey-fried licorice); the most-studied specific two-herb-pair indication for gan cao, with pharmacological evidence of paeoniflorin-glycyrrhizin antispasmodic synergy.[1]
Universal harmonizing and formula-integrating role: the indication accounting for the majority of gan cao prescriptions; not condition-specific but formula-architecture-specific; see Traditional uses above for the mechanism and significance.
Western clinical indications (condensed; full evidence base at Western licorice)
Western clinical research on licorice does not systematically distinguish G. uralensis from G. glabra; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at Western licorice.
Titration and dosing
TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.[1]
Western clinical extract dose: standardized extract equivalent to 5 to 15 g dried root daily; maximum continuous course four to six weeks without reassessment per Commission E guidance. Same limit as G. glabra.
Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both G. uralensis and G. glabra.
Effects
No effects listed yet, be the first to suggest one.
Interactions
The interaction profile of G. uralensis is identical to that of G. glabra; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at Western licorice; the following is a clinical summary.
Antihypertensive medicines: whole-licorice preparations raise blood pressure through sodium and water retention (the pseudohyperaldosteronism mechanism), directly antagonizing antihypertensive treatment; concurrent use should be avoided or blood pressure monitored closely with readiness to adjust antihypertensive doses.
Potassium-depleting medicines (loop diuretics, thiazide diuretics, corticosteroids): additive hypokalemia risk; the combination carries increased risk of clinically significant potassium depletion, muscle weakness, cardiac arrhythmia, and, at severe depletion, respiratory muscle compromise. Serum potassium monitoring is warranted in any patient combining licorice with these agents.
Cardiac glycosides (digoxin): licorice-induced hypokalemia increases myocardial sensitivity to cardiac glycoside toxicity; the combination of chronic licorice use and digoxin therapy requires concurrent potassium monitoring.
Exogenous corticosteroids: 11-beta-HSD2 inhibition by 18β-GA may amplify the mineralocorticoid effects of concurrent exogenous corticosteroid therapy, accelerating fluid retention and raising blood pressure.
A note specific to TCM formula practice: at the standard harmonizing dose (2 to 6 g daily for a short course of four weeks or less), the probability of clinically significant pharmacodynamic interaction in most patients is low. The interaction concern becomes clinically important at chronic high-dose use and in patients taking antihypertensives, diuretics, or cardiac glycosides concurrently.
DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions.
Monitoring
Whole-licorice use (any form of G. uralensis root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops.
For patients taking concurrent antihypertensive medicines or cardiac glycosides, lower the monitoring threshold: check blood pressure and potassium after two weeks of use rather than four.
DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed.
Patient counseling
The pseudohyperaldosteronism risk that applies to Western licorice (G. glabra) applies equally to Chinese licorice (G. uralensis) and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information.
The harmonizing role accounts for the majority of gan cao prescriptions and typically places it at a lower dose (2 to 6 g daily) than its use as a primary therapeutic herb. Most patients on short-course multi-herb formulae at harmonizing doses will not experience clinical pseudohyperaldosteronism. The risk rises with increasing dose, increasing duration (months rather than weeks), and pre-existing clinical vulnerability: baseline hypertension, concurrent diuretic use, and low dietary potassium intake each shift the threshold downward.
Patients who need a chronic licorice-based preparation for mucosal protection, peptic ulcer, or gastritis should be directed to deglycyrrhizinated licorice (DGL), which removes the glycyrrhizin while retaining demulcent and mucosal-protective activity. DGL does not carry the mineralocorticoid risk and does not require blood pressure or potassium monitoring; see Western licorice for the full DGL discussion including dose, formulation, and comparison with whole licorice.
Commercial licorice root products (confectionery, chewable tablets, licorice-extract beverages) may contain G. uralensis, G. glabra, or both, often without species designation and without declared glycyrrhizin content. Patients using such products as a therapeutic practice should be asked about quantity, frequency, and glycyrrhizin content where possible; "licorice root extract" on a label does not specify species or dose.
The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation.
Relevant anecdote
No anecdotes yet, share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Bensky D, Clavey S, Stoger E. Chinese Herbal Medicine: Materia Medica. 3rd ed. Eastland Press, 2004. Section on Glycyrrhiza uralensis (Gan Cao, 甘草).
- ↑ Chen WG, Ba ZM. "Prof. ZHANG Yi's experience in treating severe arrhythmia." J Tradit Chin Med 2010;30(1):47-50. PMID 20397463.